Is OrganiGram a Buy?

1 min read

Over the past year, shares of Canadian marijuana grower OrganiGram (NASDAQ: OGI) have rallied close to 60% despite what’s been a pretty lackluster business performance. To add fuel to the fire, British American Tobacco (NYSE: BTI) announced this March that it would make a strategic investment in the company. The tobacco giant will infuse CA$221 million in cash into OrganiGram in return for just under a 20% equity stake.

As exciting as that may sound, an investment in a firm that is rapidly losing money isn’t likely to turn around its operations. Many of OrganiGram’s woes still remain unresolved, and I think it’s only a matter of time before new and old investors come to their senses. In fact, its shares are already down about 16% from the time when its collaboration with British American Tobacco went public. This is definitely a stock to pass on due to its mounting losses, especially before its earnings release in the coming weeks.

Image Source: Getty Images.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Could Regeneron’s Antibody Therapy Be as Important as Vaccines in Fighting COVID?

Next Story

Lululemon Sizzles With Q4 Earnings, Revenue, and Comps Beats

Latest from Blog